Elvina Almuradova

Elvina Almuradova: Targeting c-MET overexpression is reshaping EGFR-mutant NSCLC treatment

Elvina Almuradova, Oncology Unit Lead at Can Hospitals Turkey, shared a post on X:

“Breaking News from Annals of Oncology! Targeting c-MET overexpression is reshaping EGFR-mutant NSCLC treatment!

  • Teliso-V + Osimertinib combo:
  • 50% ORR and 7.4 months PFS
  • ADCs are the future for osimertinib-resistant NSCLC!”

Elvina Almuradova: Targeting c-MET overexpression is reshaping EGFR-mutant NSCLC treatment

ADCs Annals of Oncology c-MET cancer cancer treatment advancements EGFR-mutant NSCLC Elvina Almuradova lung cancer treatment NSCLC OncoDaily Oncology osimertinib resistance Teliso-V